Linked Life Data

12691136

Source:http://linkedlifedata.com/resource/pubmed/id/12691136

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-4-14
pubmed:abstractText
FLT3, a tyrosine kinase receptor class III (RTK), and its ligand (FL) are important for normal haematopoiesis and the development of the immune system. Recently, internal tandem duplications (FLT3 ITDs) in exons 14 and/or 15 that lead to constitutive receptor activation, have been described in 20-25% of adults with acute myeloid leukaemia (AML). The FLT ITD mutations, which are thought to disrupt a repressor sequence in the juxta-membrane region, confer a poor prognosis in AML, especially in patients under the age of 60 years. Furthermore, FLT3 "activating loop" mutations involving exon 20 have been reported in 7% of AML cases, making FLT3 the most commonly mutated gene in AML. FLT3, therefore, is a potentially important molecular target for AML therapy and already phase I clinical trials have been initiated.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1042-8194
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1-7
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
pubmed:affiliation
Molecular Haematology Unit, Division of Molecular and Genetic Medicine, M floor, Royal Hallamshire Hospital, Sheffield S10 2JF, UK. j.t.reilly@sheffield.ac.uk
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't